TP53 and lymphoma: Rosuvastatin monotherapy shows a modest, allele-selective, and transient anti-tumoral effect in allograft and autochthonous T-lymphomas carrying the GOF p53 R248Q DNA contact mutation, compared to p53 null control mice (Figs. 3d–f and 4).